Catalog No.
RHJ59602
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Applications
WB
Recommended Dilution
| Application |
Dilution |
| WB |
1:500-1:1000 |
Target
SLAM family member 3, Lymphocyte antigen 9, Cell surface molecule Ly-9, T-lymphocyte surface antigen Ly-9, Signaling lymphocytic activation molecule 3, CD229, LY9, SLAMF3
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9HBG7
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R2K27
Note
For research use only.
Genetic approach to insight into the immunobiology of human dendritic cells and identification of CD84-H1, a novel CD84 homologue., PMID:11300479
Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9., PMID:11369645
XLP: one gene, many players., PMID:11414739
CD150 is a member of a family of genes that encode glycoproteins on the surface of hematopoietic cells., PMID:11486275
Activation of lymphocytes inhibits human monocyte to macrophage differentiation., PMID:11563672
CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: adhesion is mediated by Ig-like domain 1., PMID:11564780
Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells., PMID:11689425
Identification and characterization of SF2000 and SF2001, two new members of the immune receptor SLAM/CD2 family., PMID:11862385
Mouse novel Ly9: a new member of the expanding CD150 (SLAM) family of leukocyte cell-surface receptors., PMID:12242590
The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2)., PMID:12621057
Functional requirements for interactions between CD84 and Src homology 2 domain-containing proteins and their contribution to human T cell activation., PMID:12928397
Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells., PMID:15162436
Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4)., PMID:15245368
Molecular and cellular pathogenesis of X-linked lymphoproliferative disease., PMID:15661030
Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229., PMID:15879090
CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse., PMID:15905546
Fine-tuning of immune responses by SLAM-related receptors., PMID:16365151
Ly9 (CD229)-deficient mice exhibit T cell defects yet do not share several phenotypic characteristics associated with SLAM- and SAP-deficient mice., PMID:16365421
Characterization of mouse CD229 (Ly9), a leukocyte cell surface molecule of the CD150 (SLAM) family., PMID:17919264
Differential expression of SLAMS and other modulatory molecules by human plasma cells during normal maturation., PMID:20923684
Analysis of HLDA9 mAbs on plasmacytoid dendritic cells., PMID:20933012
Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells., PMID:20933013
Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010., PMID:20951742
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma., PMID:21606160
Human cytomegalovirus UL7, a homologue of the SLAM-family receptor CD229, impairs cytokine production., PMID:21670740
CD3-T cell receptor co-stimulation through SLAMF3 and SLAMF6 receptors enhances RORγt recruitment to the IL17A promoter in human T lymphocytes., PMID:22989874
Ly9 (CD229) Cell-Surface Receptor is Crucial for the Development of Spontaneous Autoantibody Production to Nuclear Antigens., PMID:23914190
Systemic lupus erythematosus immune complexes increase the expression of SLAM family members CD319 (CRACC) and CD229 (LY-9) on plasmacytoid dendritic cells and CD319 on CD56(dim) NK cells., PMID:23956418
The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection., PMID:24927415
CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma., PMID:26001047
Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases., PMID:26130131
Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents., PMID:26287276
Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses., PMID:26667173
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors., PMID:28638731
Ly9 (SLAMF3) receptor differentially regulates iNKT cell development and activation in mice., PMID:28980301
Cell surface markers for the identification and study of human naive pluripotent stem cells., PMID:29227830
Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies., PMID:29316178
The role of surface molecule CD229 in Multiple Myeloma., PMID:30326256
Ly9 (CD229) Antibody Targeting Depletes Marginal Zone and Germinal Center B Cells in Lymphoid Tissues and Reduces Salivary Gland Inflammation in a Mouse Model of Sjögren's Syndrome., PMID:30519241
Upregulation of SLAMF3 on human T cells is induced by palmitic acid through the STAT5-PI3K/Akt pathway and features the chronic inflammatory profiles of type 2 diabetes., PMID:31332162
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide., PMID:32034142
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study., PMID:32781097
CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab., PMID:33017079
Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity., PMID:35078657
Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion., PMID:35490197
CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma., PMID:35565280
Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry., PMID:35747566
Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma-An evidence-based approach., PMID:36403963
SLAMF3 promotes Th17 differentiation and is reversed by iguratimod through JAK1/STAT3 pathway in primary Sjögren's syndrome., PMID:38061117
Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab-Treated Patients With Multiple Myeloma., PMID:39267340
For research use only. Not for human or drug use.
